Of these, 3,019 patients were detected with actionable mutations in any of the eight classic NSCLC oncogenic drivers, including EGFR, ALK, BRAF, ERBB2, KRAS, MET, RET, and ROS1. EGFR was the most commonly mutated gene, detected in 66.3% (n = 2157) of the cohort (Fig. S2B). Here, KRAS is linked to non-small cell lung carcinoma.